MedTrace Logo

Gyrate Atrophy Ocular and Systemic Study

NCT05312736 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2026-01-26

No results posted yet for this study

Summary

The Gyrate Atrophy Ocular and Systemic Study characterizes the natural history of ornithine levels and retinal degeneration (RD) associated with disease-causing OAT variants in the presence of standard care dietary treatment regimens over 4 years. The research goal is to understand the impact of OAT mutations on plasma ornithine levels and retinal degeneration. Funding Source- FDA OOPD

Conditions

  • Gyrate Atrophy
  • Gyrata of Choroid and Retina; Atrophy
  • Ornithine-δ-aminotransferase
  • OAT
  • Chorioretinal Degeneration

Sponsors & Collaborators

  • Conquering Gyrate Atrophy Foundation

    collaborator UNKNOWN

  • Foundation Fighting Blindness

    collaborator OTHER

  • Jaeb Center for Health Research

    lead OTHER

Principal Investigators

  • Mandeep S. Singh, MD · John Hopkin's - Wilmer Eye Institute

  • David Valle, MD · John Hopkin's - Wilmer Eye Institute

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States
  • Brazil
  • Canada
  • Finland
  • France
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05312736 on ClinicalTrials.gov